CJC-1295 (with or without DAC)

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) developed by ConjuChem in the 2000s. Two forms are typically discussed:

• CJC-1295 with DAC (Drug Affinity Complex) — includes a maleimide group that covalently binds to serum albumin, extending half-life to ~6–8 days.
• CJC-1295 without DAC (also called 'Modified GRF 1-29' or 'Mod GRF 1-29') — shorter-acting, half-life of ~30 minutes.

ConjuChem advanced CJC-1295 into Phase 2 but development was halted. It is not FDA-approved and circulates widely in grey-market / research-chemical channels.^[1]

CJC-1295 emerged from ConjuChem's drug affinity complex (DAC) technology platform, which uses a maleimidopropionic acid linker to covalently bind a peptide to circulating serum albumin and dramatically extend its half-life. Applied to the 29-amino-acid active fragment of GHRH, the technology converted a peptide with a roughly 7-minute half-life into one circulating for days.

Two early-phase clinical studies — Teichman 2006 and Ionescu 2006 — characterized the dose-response relationship and showed sustained elevations of GH and IGF-1 over multiple days following a single dose. The development program ultimately did not progress to large-scale Phase 3 trials, and CJC-1295 has remained in the research-peptide space rather than the approved-pharmaceutical space.

Both forms stimulate the pituitary to release endogenous growth hormone through binding to the GHRH receptor. Unlike exogenous GH itself, GHRH analogs preserve the pulsatile pattern of GH release — at least in theory, this may be more physiologic.

With DAC, albumin binding creates a slow tonic signal that drives elevated baseline GH secretion. Without DAC, pulsatile 'Mod GRF 1-29' produces shorter, larger pulses when dosed.

The pharmacokinetic distinction between the two CJC-1295 forms is central to how they're discussed in the literature:

• Modified GRF 1-29 (without DAC) — half-life on the order of 30 minutes. Produces a single GH pulse mimicking the physiologic pattern when delivered with a GH secretagogue like ipamorelin.
• CJC-1295 with DAC — covalent albumin binding extends plasma half-life to 6–8 days, producing sustained GH and IGF-1 elevation rather than discrete pulses. This pharmacology is what generated the clinical interest but also raised concerns about overriding the body's normal pulsatile GH pattern.

The pulsatile-versus-sustained distinction is one of the more interesting open scientific questions for the GHRH analog class as a whole.

The peer-reviewed literature on CJC-1295 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

In historical clinical studies, CJC-1295 (with DAC) was administered weekly by subcutaneous injection. 'Mod GRF 1-29' is typically used more frequently due to its short half-life. This describes research protocols only.

CJC-1295 reliably raises GH and IGF-1. Whether modest, sustained elevation of these hormones in generally healthy adults produces meaningful improvements in body composition, recovery, or aging is the real question — and it hasn't been answered by rigorous human trials. Users experience effects (often genuine sleep improvements); whether those effects translate to worthwhile outcomes is where careful skepticism applies. Long-term cancer and metabolic risks of sustained IGF-1 elevation are non-trivial.